Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not enough participants and study funding
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Kantonsspital Münsterlingen | OTHER |
| Kantonsspital Aarau | OTHER |
| Klinik Hirslanden, Zurich | OTHER |
| Celgene Corporation |
Not provided
Not provided
Not provided
Not provided
In this study, the Myeloma Patient Outcome Scale (MyPOS) will be translated from English to German. This translated version will be quantitatively and qualitatively validated with patients with multiple myeloma.
Patients with multiple myeloma (N=10) will be interviewed in the qualitative phase about their comprehension of the translated MyPOS. The questionnaire will be revised according to the results of the interviews. This culturally adapted Swiss-German MyPOS will be assessed in the quantitative phase for its' psychometric properties with 200 patients with multiple myeloma.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MyPOS |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Myeloma Patient Outcome Scale (MyPOS) | Diagnostic Test | Patients complete the MyPOS questionnaire on quality of life |
|
| Measure | Description | Time Frame |
|---|---|---|
| Psychometric properties of the culturally-adapted Swiss-German Myeloma Patient Outcome Scale (MyPOS) | The primary outcome will be the scores on each item of the culturally-adapted Swiss-German MyPOS. Items are scored on a five-point Likert scale. For the analysis, the three subscales "Symptoms" (range: 0-52), "Emotions" (range:0-68) and "Healthcare Support" (range: 0-12) are assessed as well as the MyPOS total score (range: 0-132 ) by summing up the item scores ranging from 0-4. Higher scores reflect worse quality of life. The scores will be used to evaluate the psychometric properties of the culturally-adapted Swiss-German MyPOS:
| upon enrollment |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients with multiple myeloma
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Julia Dratva, Prof.Dr.med | Zurich University of Applied Sciences | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kantonsspital Aarau | Aarau | Canton of Zurich | 5001 | Switzerland | ||
| Kantonsspital Münsterlingen |
Not provided
| ID | Term |
|---|---|
| D009101 | Multiple Myeloma |
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
Not provided
Not provided
| INDUSTRY |
| King's College London | OTHER |
Not provided
Not provided
Not provided
| Münsterlingen |
| Thurgau |
| 8596 |
| Switzerland |
| Onkozentrum Hirslanden | Zurich | 8032 | Switzerland |
| D014652 |
| Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |